Search companies

Live

Tuesday, 17 November 2026 · 580 Summaries Today

S&P/ASX 200 · 8,883.20 (-1.79%)

OncoSil Medical Reports 46% Quarterly Sales Growth and Plans US Launch

OSL: $0.680 -5.56% · MC: $24M

OncoSil Medical reported first-quarter sales revenue up nearly half from a year earlier and plans a US commercial launch in the second half of FY27 following FDA approval for its device to treat certain bile duct cancer patients. Initial US distribution is restricted to participating academic centres, while a reimbursement application remains under review and its potential start date is uncertain. The company raised approximately $6 million from its largest institutional shareholders and ended September with approximately $9 million in cash. Earlier this week, OncoSil reported preliminary results from a small pancreatic cancer study in which all evaluable patients achieved local disease control.

Source announcements: 2026-10-30 09:17 to 2026-10-30 09:17 Sydney time
Story updated 2026-10-30 14:24 Sydney time
SourcesQuarterly Activities/Appendix 4C Cash Flow Report
Comments